DRUG BUSINESS
BUSINESS
Project No Mechanism Rights PrelND IND Dose Escalation Dose Expansion Registered Trail Difference
KN-035 PD-L1 Global

1st subcutaneous PD-L1 in the world, greatly increased convenience and reduced treatment cost

3D-185 FGFR Global

Targeting Specific signal pathway, potential combination of immunotherapy

3D-011 VEGFR/
PDGFR
Global

Targeting Specific organ, reduce systemic toxicity

  • 3D-035, no less than 5 key clinical trials respectively occurred as PhaseⅡ and PhaseⅢ, and simultaneously, the clinical trials of combination therapy occurred in multiple indications
  • 3D-011, IND Registration Application in 2019 Q1
Small Molecule Large Molecule

沪公网安备 31011202002810号